Phase II trial of nivolumab and axitinib in anti-PD-1 refractory melanoma

Yana Najjar, MD, UPMC Hillman Cancer Center, Pittsburgh, PA, discusses a Phase II trial (NCT04493203) of nivolumab and axitinib in patients with anti-PD1 refractory metastatic melanoma. The combination therapy aims to target the hypoxic tumor microenvironment to enhance immune responses, particularly in difficult-to-treat subtypes like acral and mucosal melanoma. The trial reports an encouraging disease control rate, notable stability in challenging patient groups, and favorable modulation of intratumoral hypoxia. Correlative analysis additionally shows decreased T-cell exhaustion, increased TME modulation, and manageable toxicity profiles. This interview took place at the 21st International Congress of the Society for Melanoma Research (SMR) in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.